In the last trading session, 2.23 million Halozyme Therapeutics Inc (NASDAQ:HALO) shares changed hands as the company’s beta touched 1.14. With the company’s per share price at $53.29 changed hands at $1.27 or 2.45% during last session, the market valuation stood at $6.57B. HALO’s last price was a discount, traded about -32.29% off its 52-week high of $70.50. The share price had its 52-week low at $42.01, which suggests the last value was 21.17% up since then.
Analysts gave the Halozyme Therapeutics Inc (HALO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HALO as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Halozyme Therapeutics Inc (NASDAQ:HALO) trade information
Instantly HALO was in green as seen at the end of in last trading. With action -19.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 11.47%, with the 5-day performance at -19.95% in the red. However, in the 30-day time frame, Halozyme Therapeutics Inc (NASDAQ:HALO) is -9.35% down.
The consensus price target for the stock as assigned by Wall Street analysts is 62, meaning bulls need an upside of 14.05% from its current market value. According to analyst projections, HALO’s forecast low is 62 with 62 as the target high. To hit the forecast high, the stock’s price needs a -16.34% plunge from its current level, while the stock would need to soar -16.34% for it to hit the projected low.
Halozyme Therapeutics Inc (HALO) estimates and forecasts
The 2025 estimates are for Halozyme Therapeutics Inc earnings to increase by 26.57%, but the outlook for the next 5-year period is at 28.69% per year.
Halozyme Therapeutics Inc (NASDAQ:HALO)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.1336% or 12.88 million shares worth $674.47 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Mid-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 4.16 shares estimated at $221.47 million under it, the former controlled 3.37% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.24% of the shares, roughly 4.0 shares worth around $213.06 million.
